Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Princess Anne experienced a tense journey to Glasgow due to severe weather complications. Her flight, originally scheduled to ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment ...

The Princess Royal, 74, who this weekend supported her brother, King Charles, at the Festival of Remembrance, was in the ...

DE BILT, Netherlands & GLASGOW, Scotland–(BUSINESS WIRE)–Code Pharma today announced positive eight-week results for human ...

Data presented at HIV Glasgow from the DOLCE study demonstrates our commitment to offering effective 2-drug HIV regimens, for people living with advanced HIV A post-hoc analysis shows the 2-drug ...

These data were presented at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November. Harmony P. Garges, M.D., Chief Medical Officer, at ViiV Healthcare, said: “We know taking ...

These data were presented at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November. DOLCE is a randomised, open-label, multicentre study assessing the efficacy and safety of DTG/3TC ...

Princess Anne has been dealt a blow as the royal's plane "struggled to land" amid extreme weather conditions. The Princess ...

at 06:50 Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow Gilead Sciences, Inc. today presented the first in-depth look at full results from ...